MedPath

Assessment of sarcopenic state in liver diseases and treatment efficacy by carnitine supplementatio

Not Applicable
Conditions
sarcopenia in liver diseases
Registration Number
JPRN-UMIN000030589
Lead Sponsor
Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Brief Summary

o case was admitted.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

1)The patient who has already taken carnitine 2)The patient equivalent to stageIV in hepatocellular carcinoma 3)The pregnant woman 4)The breast-feeding women 5)The patient who received other study medicine or the clinical experimental medicine within three months before dosage start of the study 6)In addition, the patient whom principal investigators judged to be inappropriate as a study subject

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Prevalence of sarcopenia in liver diseases, Treatment efficacy by carnitine supplementation(after 3months, after 6months)
Secondary Outcome Measures
NameTimeMethod
serum ammonia neuropsychiatric function test
© Copyright 2025. All Rights Reserved by MedPath